HB384 amends Kentucky’s school health statutes governing asthma and anaphylaxis medications to expressly include intranasal epinephrine alongside injectable epinephrine. It updates definitions to recognize intranasal epinephrine devices as medications used to treat anaphylaxis, and it clarifies that students with asthma or at risk of anaphylaxis may possess and use these medications at school, at school-sponsored activities, and during school-supervised times on school property.
The bill also strengthens school preparedness requirements for students with documented life-threatening allergies by allowing the required emergency epinephrine to be either injectable or intranasal and by continuing to require an individualized health care plan. It encourages schools to keep epinephrine devices in at least two accessible locations and similarly encourages keeping bronchodilator rescue inhalers in two locations, such as the office and cafeteria or athletic office, when donated or when funding is available. Schools that choose to stock these medications must adopt local policies and procedures, and the Kentucky Department for Public Health must develop clinical protocols to guide their use.
HB384 further provides civil liability protection for school employees authorized to administer medication, shielding them from ordinary negligence claims when they administer or assist with epinephrine or a bronchodilator rescue inhaler in good faith to a student believed to be experiencing a life-threatening allergic reaction, anaphylaxis, or asthma symptoms. In practical terms, the bill expands and modernizes school emergency response options while preserving the existing framework for student self-administration and school health planning.
Because no committee transcripts or recorded votes were provided, there is no direct evidence of debate or partisan division in the available materials. Based on the bill text, the measure appears to be a public-health and student-safety bill with a likely broadly supportive reception, since it adds a less invasive epinephrine delivery option and reinforces emergency preparedness in schools. Any potential concerns would likely center on implementation costs, storage and training requirements, and whether schools have sufficient funding or donated supplies to stock the medications.
Impact
HB384 would amend KRS 158.832 and KRS 158.836, Kentucky’s statutes on student asthma and anaphylaxis medication use in schools. It expands the statutory definition of medications to include intranasal epinephrine devices, authorizes their possession and use by students under existing school-medication rules, and updates school stocking and emergency-response provisions to cover either injectable or intranasal epinephrine. It also preserves and extends liability protection for authorized school employees who administer these medications in good faith, while leaving the broader school health-plan and self-administration framework in place.
Sentiment
No committee discussion or vote history was provided, so the recorded sentiment cannot be measured directly. The bill’s structure suggests generally favorable policy sentiment focused on student safety, emergency preparedness, and modernizing treatment options for allergic reactions. The inclusion of intranasal epinephrine and continued liability protections indicate an effort to make school response to anaphylaxis more practical and accessible, which would likely draw support from school health and public health advocates.
Contention
The main likely points of contention are operational rather than ideological: whether schools can afford to stock epinephrine and inhalers, whether donated supplies will be sufficient, and how schools will train staff and maintain secure but accessible storage. Another possible issue is the scope of liability protection for school employees, though the bill limits that protection to ordinary negligence and good-faith administration. No specific objections from legislators, school officials, or advocacy groups are included in the provided materials.